<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951493</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2018-14</org_study_id>
    <nct_id>NCT03951493</nct_id>
  </id_info>
  <brief_title>Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases</brief_title>
  <acronym>ZOSTER</acronym>
  <official_title>Phase III Randomized, Controlled, Open, Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypo-fractured radiotherapy in stereotactic conditions (RSHF) of bone metastases allows high
      doses to be delivered to the affected bone segment while sparing adjacent healthy tissues as
      well as possible. In addition, it not only reduces pain and prevents spinal cord compression,
      but also improves long-term control of metastatic disease.

      Zoledronic acid reduces bone complications. The economic literature shows that stereotactic
      radiotherapy, like zoledronic acid, are cost-effective strategies in these indications. The
      objective of this research project is to evaluate the efficiency of adding zoledronic acid to
      stereotactic radiotherapy in the treatment of vertebral metastases.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differential Cost Result Ratio (DCRR) expressed as cost per year of life earned in good health</measure>
    <time_frame>24 months</time_frame>
    <description>The determination of the DCRR includes Identification of care consumption ; The measurement of costs ; overall survival at 2 years ; Calculation of utilities using the EQ5D-5L questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival without vertebral compression fractures</measure>
    <time_frame>At 12 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain control</measure>
    <time_frame>at inclusion, 12 and 24 months</time_frame>
    <description>Pain control will be assessed using a visual analogue scale (VAS) that measures pain intensity, prevents it, initiates or monitors drug or non-drug treatment, and the Brief Pain inventory, a questionnaire that quickly assesses the severity of pain and its impact on the patient's daily life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without bone complication</measure>
    <time_frame>At 12 months and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Vertebral Metastasis</condition>
  <arm_group>
    <arm_group_label>RSHF + zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction. combined with zoledronic acid (4 mg IV slow monthly for 12 months, dose adjusted according to creatinine clearance).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSHF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive only RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions</intervention_name>
    <description>All patients receive radiotherapy i.e. treatment on D1, D3 and D5.
Several radiotherapy schemes are possible:
20 Gy in 1 fraction;
27 Gy in 3 fractions of 9 Gy
30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.
The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.
The injections will be carried out either at the patient's home by the nurses or in the investigator centre.</description>
    <arm_group_label>RSHF + zoledronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypo-fractured radiotherapy in stereotactic conditions</intervention_name>
    <description>All patients receive radiotherapy i.e. treatment on D1, D3 and D5.
Several radiotherapy schemes are possible:
20 Gy in 1 fraction;
27 Gy in 3 fractions of 9 Gy
30 Gy in 5 fractions of 6 Gy.</description>
    <arm_group_label>RSHF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer with inoperable thoracic and/or lumbar vertebral metastasis;

          -  Age ≥ 18 years old ;

          -  Life expectancy greater than 1 year;

          -  OMS or PS ≤ 2 ;

          -  Effective contraception for women of childbearing age;

          -  Patient information and free, informed and written consent, signed by the patient and
             investigator;

          -  Patient affiliated or beneficiary of the social security system.

        Exclusion Criteria:

          -  Cancer with inoperable thoracic and/or lumbar vertebral metastasis;

          -  Painful patient unable to maintain a lying position for 30 minutes despite analgesic
             treatment;

          -  Patient who has received external irradiation from the proposed irradiation area &gt; 20
             Gy ;

          -  Signs of neurological compression;

          -  Spinal cord compression or epidural damage requiring surgery before radiotherapy;

          -  Clinically significant hypersensitivity to zoledronic acid, other bisphosphonates or
             any excipient;

          -  History of osteonecrosis of the maxilla or bone exposure or delayed healing after
             dental surgery;

          -  Previous (less than 2 years) or ongoing treatment with a bisphosphonate;

          -  Creatinine clearance &lt; 30 ml/min;

          -  Pregnant or breastfeeding woman;

          -  Patient protected or under guardianship or incapable of giving consent;

          -  Impossibility to submit to the medical follow-up of the trial for geographical, social
             or psychological reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KAREN CLEMENT-COLMOU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO site SAINT HERBLAIN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KAREN CLEMENT-COLMOU, MD</last_name>
    <phone>0240679325</phone>
    <email>Karen.Clement-Colmou@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SUPIOT STEPHANE, MD</last_name>
    <phone>0240679913</phone>
    <email>stephane.supiot@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>JEAN-CHRISTOPHE FAIVRE, MD</last_name>
      <email>jc.faivre@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>OLIVIER CHAPET, MD</last_name>
      <email>olivier.chapet@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>RENAUD DE CREVOISIER, MD</last_name>
      <email>r.de-crevoisier@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>SEBASTIEN THUREAU, MD</last_name>
      <email>sebastien.thureau@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'OUEST</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Karen CLEMENT-COLMOU, MD</last_name>
      <phone>+33240679325</phone>
      <email>Karen.Clement-Colmou@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>NICOLAS MAGNE, MD</last_name>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypo-fractured radiotherapy in stereotactic conditions (RSHF)</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>medico-economic</keyword>
  <keyword>vertebral compressive fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

